SLSN

       SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that its prototype product, Day Mode Hero Concealer SPF 50+, has won across three prototype product/chassis categories at the 2026 Cosmetics & Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin. These awards mark Solésence's fourth year of recognition at the Allē Awards since 2022. Day Mode Hero Concealer SPF 50+ leverages three p

The report, led by the United Kingdom's APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation. From left the photo includes: Carolyn Harris, MP, Chair of the APPG for Beauty, Hair & Wellbeing, Victoria Brownlie MBE, Chief Policy & Sustainability Officer, British Beauty Council, Emma Harper, Executive Director, Strategy, Marketing, and Communications, Solésence, Jacqui Burchell, Chief Commercial Officer (CCO), British Beauty Council. ROMEOVILLE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifica

10-Q - SOLESENCE, INC. (0000883107) (Filer)

8-K - SOLESENCE, INC. (0000883107) (Filer)

Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026. "In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025," commented Kevin Cureton, President and Chief Executive Officer. "Our first quarter results reflect our disciplined execution on this initiative, particularly on o

New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment ROMEOVILLE, Ill., May 11, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the commercial availability of two proprietary platform technologies: WHSPR™ and Chromalüm™. Both technology platforms are available through finished goods for brand partners globally, and represent a significant expansion of the Company's ingredient technology portfolio. The launch of WHSPR™ and Chromalüm™ adv

8-K - SOLESENCE, INC. (0000883107) (Filer)

ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2026 after the market opens on Tuesday, May 12, 2026, and host a conference call and webcast on the same date. First Quarter 2026 Conference Call DetailsDate/Time: Tuesday, May 12, 2026 – 7:30 a.m. CT, 8:30 a.m. ET Speakers: Kevin Cureton, President & Chief Executive Officer and Laura Riffner, Chief Financial Officer Webcast Link: https://edge.media-server.com/mmc/p/t9uyyvcs Dial-In Link: https://register-conf.media-server.com/re

Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc James to its Board of Directors as an independent director, effective immediately. James will also serve as a member of the Company's Audit Committee, Compensation Committee, and Nominating Committee. The appointment reflects Solésence's continued focus on maintaining its strong corporate governance and enhancing board expertise as the Company advances its Transform & Tran

10-K/A - SOLESENCE, INC. (0000883107) (Filer)

10-K - SOLESENCE, INC. (0000883107) (Filer)

8-K - SOLESENCE, INC. (0000883107) (Filer)

Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2025. "In 2025, we achieved record revenue of $62.1 million, effectively doubling our line of consumer products in just two years. This affirmed both the value we bring to the industry, and our ability to establish ourselves as a leading innovator and manufacturer of SPF-infused beauty products," said Kevin Cureton, President and Chief Executive Officer. "In November, we launc

ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 31, 2026, and host a conference call and webcast on the same date. Fourth Quarter 2025 Conference Call DetailsDate / Time: Tuesday, March 31, 2026 – 7:30 a.m. CT, 8:30 a.m. ET Speakers: Kevin Cureton, President & CEO and Laura Riffner, Chief Financial Officer Webcast Link: https://edge.media-server.com/mmc/p/btv3gq6b Dial-In Link: https://register-conf.media-server.com/re

Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic relationships with emerging and established beauty brands, expanding Solésence's ability to deliver fully integrated, turnkey solutions that accelerate speed to market while enabling brands to deploy more working capital toward marketing and growth initiatives. "We are incredibly e

4 - SOLESENCE, INC. (0000883107) (Issuer)

4 - SOLESENCE, INC. (0000883107) (Issuer)

8-K - SOLESENCE, INC. (0000883107) (Filer)

8-K - SOLESENCE, INC. (0000883107) (Filer)

8-K - SOLESENCE, INC. (0000883107) (Filer)

10-Q - SOLESENCE, INC. (0000883107) (Filer)

Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025. Recent Highlights and Accomplishments Continued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer.Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finan

Dvorzsak to oversee product quality and drive innovation to support growth amidst evolving consumer needs; Named a Cosmetic Executive Women (CEW) Innovator Honoree ROMEOVILLE, Ill., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoana Dvorzsak to the newly created role of Vice President of Innovation and Product Integrity to support the Company's continued innovation and operational excellence in its new phase of growth. Dvorzsak will lead a newly unified group that combines Solésence's research and development, product and component de

8-K - SOLESENCE, INC. (0000883107) (Filer)

ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of 2025 before the market opens on Tuesday, November 11, 2025, and host a conference call and webcast on the same date. Third Quarter 2025 Conference Call DetailsDate / Time: Tuesday, November 11, 2025 – 7:30 a.m. CDT, 8:30 a.m. EDT Speakers: Kevin Cureton, President & CEO, Laura Riffner, Chief Financial Officer, and Jess Jankowski, Board Advisor Webcast Link: https://edge.media-server.com/mmc/p/qur8mp24 Dial-In Link: https://registe